文献速递慢性静脉疾病

微小泡沫与射频大隐静脉闭合术后消融相关血栓延伸的相关因素

Factors associated with ablation-related thrombus extension following microfoam versus radiofrequency saphenous vein closure.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2024-01-11

该回顾性研究分析了800条肢体的膝上大隐静脉闭合术,其中微小泡沫消融组96条与射频消融组150条进行比较。术后48至72小时超声显示消融相关血栓延伸在微小泡沫组的发生率为5.2%,射频组为0.7%,差异有统计学意义(P=0.02)。微小泡沫消融(P=0.045)和静脉直径大于10毫米(P=0.017)与消融相关血栓延伸独立相关。所有发生血栓延伸的患者均接受口服抗凝治疗(平均15.6天),无相关并发症。作者建议微小泡沫消融术后应常规行超声检查,并对血栓延伸患者抗凝至血栓回缩至隐股交界以下或消失。

要点

  • 微小泡沫消融术后消融相关血栓延伸发生率为5.2%,高于射频消融的0.7%(P=0.02)。
  • 微小泡沫消融(P=0.045)和静脉直径大于10毫米(P=0.017)与消融相关血栓延伸独立相关。
  • 所有血栓延伸患者接受口服抗凝治疗(平均15.6天),无相关并发症。

核心结论

  • 膝上大隐静脉闭合术后消融相关血栓延伸在微小泡沫消融后更常见。
  • 大隐静脉直径大于10毫米可能与消融相关血栓延伸相关。
  • 所有发生消融相关血栓延伸的患者接受短期抗凝治疗,无相关并发症。
  • 在更大规模的高危亚组研究完成前,微小泡沫消融术后应常规行超声检查,并对血栓延伸患者抗凝治疗直至血栓回缩至隐股交界以下或超声检查不再显示。
  • 现行学会指南不建议热消融术后常规超声检查,该建议不适用于大隐静脉非热消融微小泡沫消融术后的类似患者。

研究设计与样本

  • 回顾性分析前瞻性维护数据库,纳入2018年6月至2023年2月期间接受膝上大隐静脉闭合术的患者。
  • 共800条肢体接受治疗,其中微小泡沫消融224条,射频消融576条。
  • 微小泡沫消融组96条大隐静脉符合研究标准,射频消融组纳入同期连续150条大隐静脉作为对照。
  • 排除孤立属支静脉治疗或术后48至72小时内未行超声检查的患者。
  • 将患者分为消融相关血栓延伸组和无消融相关血栓延伸组,分析人口学、临床-病因-解剖-病理生理分级、静脉临床严重程度评分、手术细节、术后48至72小时超声发现及不良事件。

主要发现

  • 两组基线人口学特征无统计学显著差异。
  • 术后48至72小时超声检查显示6例(2.4%)发生消融相关血栓延伸,其中微小泡沫组5例(5.2%),射频组1例(0.7%),P=0.02。
  • 微小泡沫消融大隐静脉(P=0.045)和静脉直径大于10毫米(P=0.017)在单因素和多因素分析中均与消融相关血栓延伸相关。
  • 体重指数、临床-病因-解剖-病理生理分级、静脉临床严重程度评分、微小泡沫体积、手术时间和既往深静脉血栓形成不能预测消融相关血栓延伸。
  • 所有发生消融相关血栓延伸的患者接受口服抗凝治疗,平均15.6天,无相关并发症。

临床怎么用

  • 作者建议在微小泡沫消融术后常规行超声检查。
  • 作者建议对发生消融相关血栓延伸的患者进行抗凝治疗,直至血栓回缩至隐股交界以下或超声检查不再显示。
  • 作者指出,现行学会指南不建议热消融术后常规超声检查,该建议不应应用于大隐静脉非热消融微小泡沫消融术后的类似患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Polidocanol endovenous microfoam ablation (MFA) is approved by the US Food and Drug Administration for great saphenous vein (GSV) closure, yet there are few published data on the subsequent risk of ablation-related thrombus extension (ARTE). Recent societal practice guidelines recommend against routine postprocedure duplex ultrasound (DU) examination after thermal ablation of the GSV in asymptomatic patients. At present, limited data do not allow this recommendation to extend to MFA. Our aim is to identify characteristics and outcomes associated with ARTE following MFA vs radiofrequency ablation (RFA). METHODS: A retrospective review of a prospectively maintained database was conducted of patients who underwent MFA and RFA closure of incompetent above-knee GSVs. Patients treated for isolated tributary vein treatment or did not have a postprocedure DU examination within 48 to 72 hours were not included. Patients were classified into two groups: ARTE and no ARTE. Demographic data, Clinical, Etiologic, Anatomic and Pathophysiologic class, Venous Clinical Severity Score, operative details, postprocedure (48-72 hours) DU findings, and adverse events were analyzed. Variables that were significant on univariate analysis were evaluated using multivariate logistic regression with the primary outcome being development of ARTE. RESULTS: Between June 2018 and February 2023, 800 limbs were treated with either MFA (n = 224) or RFA (n = 576). Ninety-six GSVs treated with MFA met the study criteria. One hundred fifty successive GSVs treated with RFA during the same period were included as a comparison group. There was no statistically significant difference in baseline demographics between the two groups. Six patients (2.4%) demonstrated ARTE on postoperative DU examination at 48 to 72 hours (MFA, n = 5 [5.2%]; RFA, n = 1 [0.7%]; P = .02). Saphenous vein ablation with MFA (P = .045) and a vein diameter of >10 mm (P = .017) were associated with ARTE on both univariable and multivariable analysis. All patients who developed ARTE were treated with oral anticoagulants (mean, 15.6 days). Body mass index, Clinical, Etiologic, Anatomic and Pathophysiologic class, Venous Clinical Severity Score, microfoam volume, operative time, and prior deep venous thrombosis were not predictive of ARTE. CONCLUSIONS: ARTE after above-knee GSV closure occurred more frequently after MFA. Our results suggest that a saphenous vein diameter of >10 mm may be associated with ARTE. Despite this finding, all patients with ARTE were treated with short-term anticoagulation with no related complications. Until larger studies with high-risk subgroups have been studied after MFA, DU examination should be performed routinely after this procedure and patients with ARTE anticoagulated until the thrombus retracts caudal to the saphenofemoral junction or is no longer present on DU examination. Current societal guidelines recommending against routine post-thermal ablation DU examination should not be applied to similar patients after saphenous nonthermal MFA ablation.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Chin AL, Talutis SD, Lawrence PF, et al. Factors associated with ablation-related thrombus extension following microfoam versus radiofrequency saphenous vein closure. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38215907. doi:10.1016/j.jvsv.2024.101815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。